REVIEW ON THE CORONAVIRUS DISEASE (COVID-19) PANDEMIC: ITS OUTBREAK AND CURRENT STATUS
Abstract
The first incidence of the COVID-19 pandemic, which is spreading quickly, was found in Wuhan, Hubei Province, China, in December 2019. On March 11, 2020, the WHO proclaimed COVID-19 to be a pandemic due to the rapid increase in cases both in China and around the world. The disease, which mostly damages the lung parenchyma, is spread through respiratory droplets produced when infected individuals cough or sneeze. Patients with COVID-19 can experience a wide range of clinical symptoms, from asymptomatic infections to life-threatening disease. Although COVID-19 patients are most frequently affected by respiratory involvement, the virus can also harm other organ systems. The development of extra-pulmonary symptoms affecting the gastrointestinal, cardiovascular, hematological, renal, musculoskeletal, and endocrine systems is explained by the systemic inflammation caused by the disease in combination with multisystem expression of Angiotensin Converting Enzyme 2 (ACE2), a receptor that permits viral entry into cells. In this article, we've covered the wide body of literature on COVID-19 that covers a variety of clinical presentations according on the organ system affected as well as clinical presentations in certain populations like kids, pregnant women, and patients with impaired immune systems. Additionally, we briefly touched on the treatment of COVID-19. Understanding the various clinical manifestations can aid doctors in correctly diagnosing COVID-19 early on and implementing the necessary countermeasures to stop the disease's progress.
Downloads
References
[2]. Maier HJ, Bickerton E, Britton P. Coronaviruses: Methods and protocols. Coronaviruses Methods Protoc. 2015;1282(1):1–282.
[3]. Chen AT, Altschuler K, Zhan SH, Chan YA, Deverman BE. Covid-19 cg enables sars-cov-2 mutation and lineage tracking by locations and dates of interest. Elife. 2021;10:1–15.
[4]. Sharma A, Farouk IA, Lal SK. COVID-19 : A Review on the Novel Coronavirus Disease. Viruses [Internet]. 2021;13(2):1–25. Available from: https://www.mdpi.com/1999-4915/13/2/202
[5]. Koyama T, Platt D, Parida L. Variant analysis of SARS-cov-2 genomes. Bull World Health Organ. 2020;98(7):495–504.
[6]. Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health [Internet]. 2021;14(6):740–8. Available from: https://doi.org/10.1016/j.jiph.2021.03.015
[7]. Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther [Internet]. 2020;5(1). Available from: http://dx.doi.org/10.1038/s41392-020-00352-y
[8]. Mendonça SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. npj Vaccines [Internet]. 2021;6(1). Available from: http://dx.doi.org/10.1038/s41541-021-00356-x
[9]. Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology [Internet]. 2021;19(1):1–27. Available from: https://doi.org/10.1186/s12951-021-00806-7
[10]. Campillo JT, Boussinesq M, Bertout S, Faillie JL, Chesnais CB. Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-saharan africa and in the rest of the world. PLoS Negl Trop Dis. 2021;15(4):1–18.
[11]. Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg R, Bajwa N, et al. HHS Public Access. 2021;20(5):593–605.
[12]. Taleghani N, Taghipour F. Diagnosis of COVID-19 for controlling the pandemic: A review of the state-of-the-art. Biosens Bioelectron [Internet]. 2021;174:112830. Available from: https://doi.org/10.1016/j.bios.2020.112830
[13]. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory diagnosis of COVID-19: Current issues and challenges. J Clin Microbiol. 2020;58(6):1–22.
[14]. Russo A, Minichini C, Starace M, Astorri R, Calò F, Coppola N. Current status of laboratory diagnosis for covid-19: A narrative review. Infect Drug Resist. 2020;13:2657–65.
[15]. Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, et al. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med. 2021;8(June):2–10.
[16]. Mei M, Tan X. Current Strategies of Antiviral Drug Discovery for COVID-19. Front Mol Biosci. 2021;8(May).
[17]. Ang L, Song E, Lee HW, Lee MS. Herbal medicine for the treatment of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2020;9(5):1–20.
[18]. Kumara H, Minrupa B, Karunaratne S. Yoga Therapy for Immunomodulation (Prevent & Cure) of COVID-19. Int J Heal Sci Res [Internet]. 2021;11(2):130. Available from: www.ijhsr.org
[19]. Bryant A, Lawrie TA, Fordham EJ, Mitchell S. Re: Expression of Concern for Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection. Am J Ther. 2022;29:e232. Am J Ther. 2022;29(4):E455–9.
[20]. Smith T, Bushek J, Leclaire A, Prosser T. COVID-19 Drug Therapy What ’ s been updated : Highlights : Elseivier. 2020;1–25.
[21]. Canga AG, Prieto AMS, Diez Liébana MJ, Martínez NF, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans - A mini-review. AAPS J. 2008;10(1):42–6.
[22]. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J Am Med Assoc. 2020;323(18):1824–36.
[23]. Et uruta Y. Polymerase Activity (%) 100 µ mol / L Favipiravir Favipiravir-RMP Control. Proc Jpn Acad Ser B Phys Biol Sci [Internet]. 2017;93(7):449–63. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713175/pdf/pjab-93-449
[24]. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India [Internet]. 2020;76(4):370–6. Available from: https://doi.org/10.1016/j.mjafi.2020.08.004
[25]. Ahmed MH, Hassan A. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review. SN Compr Clin Med. 2020;2(12):2637–46.
[26]. Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345–52.
[27]. Satarker S, Ahuja T, Banerjee M, E VB, Dogra S, Agarwal T, et al. Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. Curr Pharmacol Reports. 2020;6(5):203–11.
[28]. Dixit PK, Gupta S, Prasad AS, Kohli K, Ghana P. Side effects of hydroxychloroquine prophylaxis against COVID-19 in healthcare workers. Med J Armed Forces India [Internet]. 2021;77:S513–4. Available from: https://doi.org/10.1016/j.mjafi.2020.11.016
[29]. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep [Internet]. 2021;11(1):1–12. Available from: https://doi.org/10.1038/s41598-021-95565-8
[30]. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. Front Med. 2021;8(May).
[31]. https://www.who.int/
[32]. https:/www.gavi.org/
[33]. https:/www.afro.who.int/
[34]. Drugs.com.
[35]. Robin E Ferner(26 June 2020);Drug Vignettes:Dexamethasone
[36]. Huzefakifayet (21April 2020):Lopinavirsynthesis,SAR,MCQ,structure,chemical properties &Terapeutics uses.
[37]. Marco Cascella (January 6 2022) Features,Evaluation& Treatment of covid-19.
[38]. National comprehensive guidelines for management of post covidsequelae.Ministry of health & family welfare Govt.of.India
[39]. Emma Ladds;Persistent syndrome after covid-19:Qualitative study of 114 'long covid' patient & draft quality principles for services.https://doi.org/10.1186/s12912-020-06001-y
[40]. Amy D. Proal(June 23 2021);Long Covid or post acute sequelae of covid-19(PASC):An overview of biological factors that may contribute to persistent symptoms
[41]. CDC(16 Sep 2021)Centers for Disease control & prevention
[42]. Covid-19(coronaviruses):long term effects(22 Oct 2021)
[43]. Ani Nalbandian (April 2021);Post – acute covid-19 syndrome
[44]. Trisha Greenhalgh(11 Aug 2020);Management of post covid-19 in primary care
[45]. Marco Cascella 5 Jan 2022;Features,evaluation & treatment of coronaviruses (covid-19)
Copyright (c) 2023 IJRDO-Journal of Applied Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the IJRDO Journal will have the full right to remove the published article on any misconduct found in the published article.
